Modified L-nucleic acid

US7629456B2 · kind B2 · utility

Assignee

• NOXXON Pharma AG · DE

Inventors

• Christian Lange · Frankfurt am Main, DE
• Bernd Eschgfaller · Basel, CH
• Sven Klussmann · Berlin, DE

Key dates

• Filing date: Oct 25, 2002
• Grant date: Dec 8, 2009
• Expiry date: Dec 8, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a modified L-nucleic acid, comprising a L-nucleic acid part and a non-L-nucleic acid part, whereby the L-nucleic acid part is conjugated to the non-L-nucleic acid part and the conjugation of the L-nucleic acid part with the non-L-nucleic acid past leads to a slowed elimination out of the organism, in comparison with a L-nucleic acid which only comprises the L-nucleic acid part, said L-nucleic acid part being a spiegelmer.